Still in the Dark…

#PCWG4 launched #GU26 w/aspirational reliance on #PSMA imaging for drug development

But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging

#PSMAdark
@ascocancer.bsky.social

@melissaabel20 et al
rdcu.be/eKNQe

Still in the Dark…

#PCWG4 launched @ascocancer.bsky.social #GU26 w/aspirational reliance on #PSMA imaging for drug development

But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging

#PSMAdark

@melissaabel20 et al
rdcu.be/eKNQe